Physician Views: Can Lundbeck and Otsukas newly approved Rexulti compete with branded and generic competition in the schizophrenia and depression markets?

Physician Views: Can Lundbeck and Otsukas newly approved Rexulti compete with branded and generic competition in the schizophrenia and depression markets?

Code: FW-20150709 | Published: Jul-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






FDA approval of Lundbeck and Otsuka Pharmaceuticals Rexulti - which was announced last week - delivers a third atypical antipsychotic to the US market for the treatment of both schizophrenia and major depressive disorder (MDD).

Rexulti will not only compete with Abilify and Seroquel XR, but generic versions of the former - the branded also marketed by Otsuka - which have been available since US patent expiration in April. While FDA approval of Rexulti in both schizophrenia and MDD with similar labelling to competitors frames a "best case scenario" for the drug, remarked analysts at Jefferies, questions remain as to whether Lundbeck and Otsuka can sufficiently differentiate Rexulti from these competitors.

With Rexulti positioned as a successor to Abilify, Otsuka expects blockbuster sales to be achieved. The size of the US market for schizophrenia and MDD therapies, coupled with demand for new approaches to treatment, are supportive of such aspirations, suggest analysts at Credit Suisse. In a note to investors detailing approval of Rexulti last week, analysts at Deutsche Bank indicated that an improved tolerability profile versus Abilify could provide the best opportunity for Rexulti to emerge from the shadow of competition.

Given the size of the market, added analysts at Jefferies, "while Rexulti may struggle to compete with established market-leading brands, if a new drug is able to become a second or third-line alternative and capture a small share of the market it could generate blockbuster revenues."








To better assess the pending launch of Rexulti in the US market, FirstWord is polling US-based psychiatrists and primary care practitioners with the following questions


- Based on pivotal-stage data (http://investor.lundbeck.com/releasedetail.cfm?
ReleaseID=921621), what is your assessment of Rexultis (brexpiprazole) clinical profile?

- Based on the same data, do you believe Rexulti is differentiated from Abilify and Seroquel XR?

- Based on the same data, what is your assessment of Rexultis tolerability profile versus existing atypical antipsychotics approved for major depressive disorder and schizophrenia?

- Factoring in the recent availability of generic Abilify in what line of therapy would you most likely use Rexulti for the treatment of schizophrenia?

- Factoring in the recent availability of generic Abilify in what line of therapy would you most likely use Rexulti for the treatment of major depressive disorder?



Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients